Dendrimers for gene delivery – a potential approach for ocular therapy?
- 1 April 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 66 (4) , 542-556
Abstract
Objectives: A vast number of blinding diseases have genetic aetiologies and may be treated by molecular based therapies such as antisense oligonucleotides or short interfering RNA. However, treatment success of ocular gene therapy is highly dependent on efficient delivery of such molecules. Key findings: The majority of clinical studies for ocular gene therapy utilize viral vectors. While these have proven highly efficient, they show limited loading capacity and pose significant safety risks owing to their oncogenic and immunogenic effects. Non-viral gene carriers have emerged as a promising alternative with dendrimers providing great potential for gene therapy because of their size, shape and high density of modifiable surface groups. However, while dendrimers have been used extensively for drug and gene delivery to other organs, only a few studies have been reported on the eye. Summary: This review focuses on the development of dendrimers for gene delivery with special emphasis on ocular gene therapy. Different synthesis approaches and types of dendrimers are discussed. Ocular gene therapy targets are highlighted with an overview of current clinical studies. The use of dendrimers in ocular gene delivery in comparison to liposomes and nanoparticles is also discussed. Finally, future prospects of tailored multifunctional dendrimers for ocular gene therapy are highlighted.Keywords
This publication has 104 references indexed in Scilit:
- Targeted Administration into the Suprachoroidal Space Using a Microneedle for Drug Delivery to the Posterior Segment of the EyeInvestigative Ophthalmology & Visual Science, 2012
- Nanoparticle-Mediated Delivery of shRNA.VEGF-A Plasmids Regresses Corneal NeovascularizationInvestigative Ophthalmology & Visual Science, 2012
- Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded SafetyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Gene therapy in the Cornea: 2005–presentProgress in Retinal and Eye Research, 2012
- SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in HumansPLOS ONE, 2011
- Polymers in Small-Interfering RNA DeliveryNucleic Acid Therapeutics, 2011
- Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical ApplicationsInvestigative Ophthalmology & Visual Science, 2010
- Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skinVision Research, 2010
- Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivoJournal of Controlled Release, 2008
- Challenges in non-viral ocular gene transferBiochemical Society Transactions, 2007